반응식
[OH:1][CH2:2][CH2:3][CH2:4][CH2:5][CH2:6][CH2:7][N:8]1[CH2:13][CH2:12][CH:11]([C:14]2[C:18]3[CH:19]=[CH:20][C:21]([F:23])=[CH:22][C:17]=3[O:16][N:15]=2)[CH2:10][CH2:9]1.[CH2:24]1[O:32][C:31]2[CH:30]=[CH:29][C:28]([N:33]=[C:34]=[O:35])=[CH:27][C:26]=2[O:25]1>>[CH2:24]1[O:32][C:31]2[CH:30]=[CH:29][C:28]([NH:33][C:34]([O:1][CH2:2][CH2:3][CH2:4][CH2:5][CH2:6][CH2:7][N:8]3[CH2:9][CH2:10][CH:11]([C:14]4[C:18]5[CH:19]=[CH:20][C:21]([F:23])=[CH:22][C:17]=5[O:16][N:15]=4)[CH2:12][CH2:13]3)=[O:35])=[CH:27][C:26]=2[O:25]1참가 물질
3
실험 절차
Starting from 3-[1-(1-hydroxyhex-6-yl]-4-piperidinyl]-6-fluoro-1,2-benzisoxazole (270 mg, 0.84 mmol) and 3,4-methylenedioxyphenylisocyanate (297 mg, 1.69 mmol) using the procedure described in example 12B was prepared 210 mg (51.8%) of the title compound as an amorphous solid.
출처 및 근거
- ORD 기록
- ord-047b409873fe48d9bbfdd02e700861fb
- 출처 데이터셋
- uspto-grants-1995_01
- 특허 번호
- US05378714
연결된 노트
불러오는 중…